---
title: "Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293737344.md"
description: "Outlook Therapeutics granted stock options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon, with effective dates of July 21, 2026. The company also approved performance-linked cash bonuses tied to the FDA approval of ONS-5010. These awards recognize the executives' efforts in advancing the ONS-5010 BLA through FDA review and appeals."
datetime: "2026-07-24T10:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293737344.md)
  - [en](https://longbridge.com/en/news/293737344.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293737344.md)
generator: "portal-rs"
---

# Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon

**Outlook Therapeutics granted stock options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon and approved performance-linked cash bonuses tied to FDA approval of ONS-5010.**

**Individual**

Robert C. Jahr

Lawrence A. Kenyon

**Role**

Chief Executive Officer

Chief Financial Officer

**Type of Change**

Option award granted; bonus opportunity approved

Option award granted; bonus opportunity approved

**Effective Date**

July 21, 2026 (options vest July 21, 2027)

July 21, 2026 (options vest July 21, 2027)

**Reason**

Recognition of efforts advancing ONS-5010 BLA through FDA review and appeals; no 2025 annual bonus paid

Recognition of efforts advancing ONS-5010 BLA through FDA review and appeals; no 2025 annual bonus paid

**Replacement Info**

Not disclosed

Not disclosed

**Background Details**

100,000 options granted under 2024 Plan; exercise price $1.4304; vesting contingent on continued service (max 200 chars)

210,078 options granted under 2024 Plan; exercise price $1.4304; vesting contingent on continued service (max 200 chars)

**Board/Committee Role Changes**

Not disclosed

Not disclosed

Original SEC Filing: Outlook Therapeutics, Inc. \[ OTLK \] - 8-K - Jul. 23, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [OTLK.US](https://longbridge.com/en/quote/OTLK.US.md)

## Related News & Research

- [Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary](https://longbridge.com/en/news/296273184.md)
- [Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9](https://longbridge.com/en/news/295983837.md)
- [Spruce Biosciences targets Q4 2026 BLA filing for TA-ERT in Sanfilippo syndrome type B after FDA meetings](https://longbridge.com/en/news/296784399.md)
- [Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis](https://longbridge.com/en/news/296776870.md)
- [Lexston Mining Corporation Announces Stock Option Grant](https://longbridge.com/en/news/296656725.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**